指南与共识胰腺与胆道疾病消化内镜

超声内镜引导下细针活检取样对国际共识诊断标准诊断自身免疫性胰腺炎的影响:一项前瞻性多中心研究

Impact of EUS-guided fine-needle biopsy sampling on International Consensus Diagnostic Criteria for diagnosing autoimmune pancreatitis: a prospective multicenter study.
指南 / 共识 · Gastrointest Endosc · 2025-02-28

这项前瞻性多中心研究纳入52例疑似自身免疫性胰腺炎(AIP)的成人患者,评估22G端切式穿刺针行超声内镜引导下细针活检(EUS-FNB)能否提升国际共识诊断标准(ICDC)的诊断等级并明确AIP亚型。结果显示EUS-FNB使92.3%的患者ICDC诊断等级得到提升,总体诊断准确率为94.2%(95%CI,84.1-98.8),术后发生2例轻度胰腺炎(3.8%)。

要点

  • EUS-FNB使92.3%的疑似AIP患者ICDC诊断等级提升,其中74.3%达确诊、17.9%达疑似。
  • 1型AIP组织学1级符合率为73.1%、2级为23.1%;2型分别为50%和41.7%。
  • EUS-FNB总体诊断准确率94.2%(95%CI,84.1-98.8),术后轻度胰腺炎发生率3.8%。

核心结论

  • 使用端切式穿刺针的EUS-FNB在超过90%的患者中提升了ICDC诊断等级,可在局灶性表现中排除恶性肿瘤并明确AIP的具体亚型。

研究设计与样本

  • 前瞻性多中心研究,在4个中心竞争性入组疑似AIP的成人患者,排除按ICDC已确诊AIP或近期接受激素治疗者,全部使用22G端切式穿刺针。

主要发现

  • 共入组52例患者(男性75%,平均年龄57.9±17.3岁),其中局灶性病变50例、弥漫性病变2例。
  • 最终诊断为AIP 39例(75%)、慢性胰腺炎6例(11.5%)、恶性肿瘤7例(13.5%)。
  • EUS-FNB使92.3%的患者AIP诊断等级提升,其中74.3%达确诊、17.9%达疑似。
  • 1型AIP组织学1级符合率为73.1%、2级为23.1%;2型AIP组织学1级符合率为50%、2级为41.7%。
  • EUS-FNB总体诊断准确率为94.2%(95%CI,84.1-98.8),EUS-FNB后发生2例轻度胰腺炎(3.8%)。

关键数值与推荐

  • 主要结局为ICDC诊断等级提升率,次要结局包括1级或2级率、EUS-FNB诊断准确率、恶性肿瘤检出率和安全性。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Histologic diagnosis of autoimmune pancreatitis (AIP) may be difficult to obtain preoperatively. Based on promising results using new-generation "end-cutting" needles, we aimed to assess the utility of EUS-guided fine-needle biopsy (EUS-FNB) sampling in enhancing diagnostic levels of International Consensus Diagnostic Criteria (ICDC) in patients with probable AIP and in defining the specific AIP subtype. METHODS: Adult patients with suspected AIP were prospectively and competitively enrolled at 4 centers. Definitive AIP diagnosis, according to the ICDC, or patients recently treated with steroids were excluded. A 22-gauge end-cutting needle was used in all cases. The primary outcome was the rate of enhanced ICDC levels. Secondary outcomes were rates of levels 1 or 2, EUS-FNB diagnostic accuracy, rate of malignancy, and safety. RESULTS: Fifty-two patients with focal (50) and diffuse (2) suspected AIP were enrolled (75% men; mean age, 57.9 ± 17.3 years). Final diagnoses were AIP, chronic pancreatitis, and malignancy in 39 (75%), 6 (11.5%), and 7 (13.5%) patients, respectively. EUS-FNB improved the diagnostic level of AIP in 92.3% (74.3% definitive and 17.9% probable). The rate of histology level 1 compatible with a diagnosis of type 1 and type 2 AIP was 73.1% and 50%, respectively. The rate of histology level 2 was 23.1% and 41.7% in type 1 and type 2, respectively. The overall diagnostic accuracy of EUS-FNB was 94.2% (95% CI, 84.1-98.8). Two mild cases of pancreatitis (3.8%) occurred after EUS-FNB. CONCLUSIONS: EUS-FNB using end-cutting needles enhanced the ICDC in >90% of patients, ruling out malignancy in focal presentations and defining the specific subtype of AIP. (Clinical trial registration number: NCT04397731.).

来源:Gastrointest Endosc,查看原文。版权归原作者所有。

引用

  1. Conti Bellocchi MC, Crinò SF, Ikeura T, et al. Impact of EUS-guided fine-needle biopsy sampling on International Consensus Diagnostic Criteria for diagnosing autoimmune pancreatitis: a prospective multicenter study. Gastrointest Endosc. 2025. PMID: 40024297. doi:10.1016/j.gie.2025.02.038

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。